Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma - Concepedia

Concepedia

Publication | Closed Access

Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma

52

Citations

29

References

2004

Year

Miklos Pless, Karim Belhadj, Hans D. Menssen, Wolfgang Kern, Bertrand Coiffier, Jürgen Wolf, Richard Herrmann, Eckhard Thiel, Doug Bootle, I. Sklenar,

Clinical Cancer Research

Abstract

SAM486A has a promising clinical activity in patients with poor prognosis NHL and manageable safety profile. To further define the role of SAM486A, in the treatment of NHL, additional studies are warranted.

References

	Year	Citations

Page 1